Consistent with the results of the present review, some independent case-control studies have suggested that methylated SEPT9 in plasma can be used to identify individuals with CRC with 0.52–0.72 sensitivity and 0.90–0.95specificity [14, 16]. Here, SEPTIN9 is linked to colorectal carcinoma.